IVIEW Therapeutics Abstract Accepted for On-Demand Poster Presentation at AAO 2025 Study Showcases Clinical Potential of TRPM8 Agonist IVW-1001 in Dry Eye Disease

[Cranbury, New Jersey, October 1, 2025]We are proud to announce that our abstract, “Eyelid Margin Delivery of a TRPM8 Agonist IVW-1001 Relieves Symptoms in Dry Eye Disease: A Phase 1/2a Study,” has been officially accepted as an On-Demand Poster at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting. Out of more than 2,300 submissions this year, only 744 posters were selected, underscoring the quality and significance of our research. We are honored to share our work at the world’s largest association of eye physicians and surgeons, representing over 32,000 members globally. The study, to be presented by Lee Shettle, D.O., highlights the promising clinical potential of IVW-1001, a TRPM8 agonist, for relieving symptoms in patients with Dry Eye Disease. This innovative delivery method via the eyelid margin may offer a new approach for improving patient comfort and quality of life. The poster will be available for on-demand viewing through the AAO 2025 virtual platform this October, providing ophthalmologists worldwide with access to our findings. The American Academy of Ophthalmology is dedicated to protecting sight and empowering lives by leading ophthalmic education and supporting groundbreaking research. We are thrilled to contribute to this mission and advance the science of eye care. We extend our deepest thanks to our dedicated research team and collaborators, whose expertise and commitment made this milestone possible. About IVIEW Therapeutics Inc. IVIEW Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative ophthalmic therapies. We invest in novel mechanisms of action and differentiated drug delivery platforms to create therapies with superior clinical profiles that address significant unmet medical needs. Our pipeline includes small molecules and gene therapies for dry eye, myopia, conjunctivitis, glaucoma, and presbyopia. The U.S. headquarters is in Cranbury, New Jersey, with 11,045 square feet of combined laboratory and office space in the Princeton area. For additional information, please visit www.iviewtherapeutics.com Media Contact: Email: [email protected]

The release as fetched from its publisher. iviewtherapeutics.com ↗